First Bank & Trust Has $4.59 Million Stake in Pfizer Inc. $PFE

First Bank & Trust lifted its stake in Pfizer Inc. (NYSE:PFE) by 21.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 184,140 shares of the biopharmaceutical company’s stock after acquiring an additional 32,523 shares during the quarter. Pfizer comprises 0.7% of First Bank & Trust’s portfolio, making the stock its 24th largest holding. First Bank & Trust’s holdings in Pfizer were worth $4,585,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer in the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer during the 2nd quarter valued at $30,000. True Wealth Design LLC grew its holdings in shares of Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 974 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Pfizer in the second quarter worth $32,000. Finally, Sagard Holdings Management Inc. acquired a new position in shares of Pfizer in the second quarter worth $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE PFE opened at $27.29 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The stock’s 50-day moving average is $26.78 and its two-hundred day moving average is $25.65. The firm has a market cap of $155.16 billion, a P/E ratio of 20.06 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the business earned $0.63 EPS. The firm’s revenue was down 1.2% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline for TALAPRO-3 (TALZENNA + XTANDI) in homologous recombination repair prostate cancer — strengthens Pfizer’s oncology franchise and supports future revenue and labeling opportunities. Pfizer Announces Positive TALAPRO-3 Results
• Positive Sentiment: Guggenheim raised its price target to $36 and upgraded to a buy — a high-profile analyst lift that can drive demand and re-rate the stock if others follow. Benzinga: Guggenheim Raises Price Target
• Positive Sentiment: Analyst and media bullishness on upside from a key prostate‑cancer trial — several write-ups project significant appreciation (examples cite targets near $36) if oncology readouts continue to progress. 247WallSt: Pfizer Could Hit $36
• Positive Sentiment: Coverage highlighting Pfizer as a high‑yield, undervalued play with pipeline catalysts — these narratives attract income and value buyers while emphasizing long‑term upside from new assets. 24/7 Wall St: 6.5% Yielding Dividend Payer
• Positive Sentiment: Pfizer CFO discussed recent oncology milestones on NYSE Live — management visibility on progress helps reduce execution uncertainty and supports investor confidence. Yahoo Finance: CFO Highlights Oncology Milestones
• Neutral Sentiment: Company scheduled a public webcast and analyst call for May 5 to discuss Q1 results and the Q1 performance report — provides a near-term event for updated guidance and pipeline commentary. Yahoo Finance: May 5 Webcast
• Negative Sentiment: Lyme vaccine readout shows ~73% efficacy but missed the trial’s primary statistical target due to low case numbers — clinical/regulatory uncertainty remains and could delay approvals or reduce near-term impact. Yahoo Finance: Pfizer Lyme Vaccine Data
• Negative Sentiment: Competitor momentum: Bristol Myers’ Opdivo label expansions intensify IO competition — pricing and market-share pressure in oncology could constrain long‑term upside for some Pfizer programs. Yahoo Finance: BMY Opdivo Expansion
• Negative Sentiment: Valneva’s stock plunge after mixed Lyme results highlights partner/regulatory risk — market volatility in related vaccine news can spill over to Pfizer sentiment. Yahoo Finance: VALN Mixed Results

Analyst Ratings Changes

A number of research firms recently issued reports on PFE. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Guggenheim boosted their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank Of Canada started coverage on Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.19.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.